Skip to main content

Table 4 Performance of different markers for outcome prediction on the independent test set.

From: Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes

 

Accuracy

Sensitivity

Specificity

Microarray classifier

0.77, [0.66;0.85], (23/30)

0.86, [0.62;0.96], (6/7)

0.74, [0.61;0.84], (17/23)

Age

0.53, [0.42;0.65], (16/30)

1.0, [0.81;1.0], (7/7)

0.39, [0.27;0.52], (9/23)

Stage

0.60, [0.48;0.71], (18/30)

1.0, [0.81;1.0], (7/7)

0.48, [0.35;0.61], (11/23)

Age + Stage

0.70, [0.58;0.79], (21/30)

1.0, [0.81;1.0], (7/7)

0.61, [0.48;0.73], (14/23)

  1. The figures in brackets denote 95% confidence intervals and absolute number of cases. For prediction of outcome by age at diagnosis, patients older than one year were predicted with unfavourable outcome. For prediction by stage, patients with stage 3 were predicted with favourable outcome and patients with stage 4 were predicted with unfavourable outcome. For the combination of the markers age and stage, only stage 4 patients older than one year at dignosis were predicted with unfavourable outcome. Sensitivity/Specificity is rate of correctly predicted patients with unfavourable/favourable outcome.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us